CY2022015I2 - Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι - Google Patents

Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι

Info

Publication number
CY2022015I2
CY2022015I2 CY2022015C CY2022015C CY2022015I2 CY 2022015 I2 CY2022015 I2 CY 2022015I2 CY 2022015 C CY2022015 C CY 2022015C CY 2022015 C CY2022015 C CY 2022015C CY 2022015 I2 CY2022015 I2 CY 2022015I2
Authority
CY
Cyprus
Prior art keywords
methods
long
related compositions
compstatin analogs
acting compstatin
Prior art date
Application number
CY2022015C
Other languages
English (en)
Other versions
CY2022015I1 (el
Original Assignee
Apellis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/070417 external-priority patent/WO2014078731A2/en
Application filed by Apellis Pharmaceuticals, Inc. filed Critical Apellis Pharmaceuticals, Inc.
Publication of CY2022015I1 publication Critical patent/CY2022015I1/el
Publication of CY2022015I2 publication Critical patent/CY2022015I2/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY2022015C 2012-11-15 2022-06-09 Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι CY2022015I2 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261727094P 2012-11-15 2012-11-15
US201261727093P 2012-11-15 2012-11-15
PCT/US2013/070417 WO2014078731A2 (en) 2012-11-15 2013-11-15 Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
EP13854990.2A EP2920201B1 (en) 2012-11-15 2013-11-15 Long-acting compstatin analogs and related compositions and methods

Publications (2)

Publication Number Publication Date
CY2022015I1 CY2022015I1 (el) 2023-01-05
CY2022015I2 true CY2022015I2 (el) 2023-01-05

Family

ID=50731834

Family Applications (1)

Application Number Title Priority Date Filing Date
CY2022015C CY2022015I2 (el) 2012-11-15 2022-06-09 Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι

Country Status (3)

Country Link
US (3) US20160194359A1 (el)
CY (1) CY2022015I2 (el)
WO (1) WO2014078734A2 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
MX356528B (es) 2011-05-11 2018-06-01 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US11903994B2 (en) * 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
RU2019113301A (ru) 2016-10-17 2020-11-17 Апеллис Фармасьютикалс, Инк. Комбинированная терапия для ингибирования с3
KR20180091773A (ko) * 2017-02-07 2018-08-16 한미약품 주식회사 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
RU2020128624A (ru) * 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
EP4011905A3 (en) 2018-04-06 2022-06-29 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ, インコーポレーテッド 医学的障害の治療のための大環状化合物
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
WO2020131974A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
BR112021018456A2 (pt) 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
US12312607B2 (en) * 2019-05-24 2025-05-27 Avitide LLC AAV9 affinity agents
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
EP4398926A4 (en) * 2021-09-09 2025-07-02 Apellis Pharmaceuticals Inc TREATMENT OF GEOGRAPHIC ATROPHY
TWI818431B (zh) * 2022-02-08 2023-10-11 高雄醫學大學 雙環壬炔衍生物及其製備方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1549333E (pt) * 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN102977191B (zh) * 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物

Also Published As

Publication number Publication date
US20160194359A1 (en) 2016-07-07
CY2022015I1 (el) 2023-01-05
US20170283461A1 (en) 2017-10-05
WO2014078734A2 (en) 2014-05-22
US20200325175A1 (en) 2020-10-15
WO2014078734A3 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
CY2022015I1 (el) Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι
HUS2200026I1 (hu) Hosszan ható compstatin-analógok és kapcsolódó készítmények, valamint módszerek
FR24C1043I2 (fr) Analogues du glucagon
SMT202100154T1 (it) Composizioni e metodi per identificare precisamente mutazioni
LT3725778T (lt) Enzalutamido kompozicijos
LT2791160T (lt) Modifikuotos mrnr sudėtys
EP2787837A4 (en) COMMONLY DECOMPOSED STABILIZER COMPOSITION
BR112014032798A2 (pt) composição
DK2931970T4 (da) Cellulose-afledte sammensætninger
DK2841054T3 (da) Injicerbart præparat
ME03413B (me) Kompozicije које sadrže peg i askorbat
IL237914A0 (en) Benzamides
DK2844309T3 (da) Selektivt polymeriserbare sammensætninger
DK2868318T3 (da) Injicerbar formulering
DK2897594T3 (da) Farmaceutisk sammensætning
DK2877155T3 (da) Opioidformuleringer
PT2836483T (pt) Agentes antimalária
FR2988426B1 (fr) Plate-forme inter-aubes
FR2988427B1 (fr) Plate-forme inter-aubes
BR112014032712A2 (pt) composição
HUE049445T2 (hu) Új kompozíciók
BR112015002646A2 (pt) composto e composição farmacêutica
EP2914233A4 (en) DENTAL COMPOSITIONS
DK2811828T3 (da) Adjuvanssammensætninger
EP2837670A4 (en) Fluorobiphenyl-containing composition